Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 19/20 | 1.00 |
| ▸ | LTB4R2 | Q9NPC1 | 10/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354842 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL1447495 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL29369941 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL8941433 | 0.95 | LTB4R (0.91) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL8957158 | 0.92 | LTB4R (0.85) | LTB4RLTB4R2 | |
| SCHEMBL8941451 | 0.91 | LTB4R (0.84) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL8941328 | 0.91 | LTB4R (0.83) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL8941563 | 0.88 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL8957249 | 0.87 | LTB4R (0.77) | LTB4RLTB4R2 | |
| SCHEMBL5694677 | 0.86 | LTB4R (0.76) | LTB4RLTB4R2CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190216790-A1 | Methods for Treating Pruritis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | claimed |
| WO-2018071687-A1 | METHODS OF TREATING PRURITIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-19 | — | — | WO | claimed |
| WO-2001034134-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2001034199-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| EP-0593478-B1 | LEUKOTRIENE B 4 ANTAGONISTS | SEARLE & CO (US) | 1995-12-06 | — | — | EP | claimed |
| US-5310951-A | Benzopyran-2-propanoic acid derivatives; antiinflammatory agents | G.D. SEARLE & CO. (US) | 1994-05-10 | — | — | US | claimed |
| EP-0593478-A1 | LEUKOTRIENE B 4? ANTAGONISTS. | SEARLE & CO (US) | 1994-04-27 | — | — | EP | claimed |
| US-5124350-A | Antiinflammatory agent | G. D. SEARLE & CO. (US) | 1992-06-23 | — | — | US | claimed |
| WO-1992000011-A2 | LEUKOTRIENE B4 ANTAGONISTS | G.D. SEARLE & CO. (US) | 1992-01-09 | — | — | WO | claimed |
| US-20190216790-A1 | Methods for Treating Pruritis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | disclosed |
| EP-2471954-B1 | Genetic susceptibility variants associated with cardiovascular disease | DECODE GENETICS EHF (IS) | 2016-08-24 | — | — | EP | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| EP-2155907-B1 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENT OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION | DECODE GENETICS EHF (IS) | 2015-05-27 | — | — | EP | disclosed |
| EP-0593478-B1 | LEUKOTRIENE B 4 ANTAGONISTS | SEARLE & CO (US) | 1995-12-06 | — | — | EP | disclosed |
| US-5439937-A | Leukotriene B4 antagonists | G. D. SEARLE & CO. (US) | 1995-08-08 | — | — | US | disclosed |
| US-5310951-A | Benzopyran-2-propanoic acid derivatives; antiinflammatory agents | G.D. SEARLE & CO. (US) | 1994-05-10 | — | — | US | disclosed |
| EP-0593478-A1 | LEUKOTRIENE B 4? ANTAGONISTS. | SEARLE & CO (US) | 1994-04-27 | — | — | EP | disclosed |
| US-5124350-A | Antiinflammatory agent | G. D. SEARLE & CO. (US) | 1992-06-23 | — | — | US | disclosed |
| WO-1992000011-A2 | LEUKOTRIENE B4 ANTAGONISTS | G.D. SEARLE & CO. (US) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216790-A1 | Methods for Treating Pruritis | ITCH, CYSLTR2, CYSLTR1 | LTB4R 8/4885LTB4R2 4/4885CYSLTR2 2/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | LTB4R 8/4885LTB4R2 7/4885CYSLTR2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.